Efzimfotase alfa shows positive Phase III results in hypophosphatasia
Efzimfotase alfa demonstrated significant improvement in bone health in treatment-naïve pediatric patients and maintained safety in those previously treated with Strensiq.
Therapeutic Area
Therapeutic area intelligence for Rare Diseases with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No related entities indexed yet.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.